title: Suitability of Gelucire 50/13 for controlled release formulation of salbutamol sulphate.
abstract: Gelucire 50/13 (G50/13) was assessed to develop controlled release formulation of salbutamol sulphate (SBL) a highly water soluble drug by semisolid matrix filling capsule technique. Drug release profiles of SBL release by using G50/13 and its blends with other hydrophilic or hydrophobic materials were investigated. Lipid matrix formulations prepared with increasing amount of polymer showed a substantial decrease in release rate of the drug while increasing drug amount in fixed polymer concentration did not significantly affect the release profile. Polyethylene glycol 6000 caused an increased water uptake resulting in fast erosion of the matrix whereas cetostearyl alcohol and stearic acid caused retardation in drug release. These findings confirm that a considerable amount of Gelucire is required alone or in combination with hydrophobic substances in order to sustain the release profiles of water soluble drugs. More linear profile was obtained by using matrix comprising Gelucire/stearic acid blend in more than 85% that was comparable to standard, Ventolin SR tablet. The test formulation showed a significant decrease at pH 1.0 and the drug release rate increased at high stirring speed. Moreover, short term stability of controlled release test formulation indicated slight increase in dissolution rate at high temperature.
authors.affiliation: Department of Pharmaceutical Sciences, COMSATS Institute of Information Technology, Abbottabad, Pakistan.
authors.forename: Sabeeh
authors.initials: S
authors.lastname: Mohsin
authors.forename: Nisar-Ur
authors.initials: NU
authors.lastname: Rahman
authors.forename: Muneeb Ahmad
authors.initials: MA
authors.lastname: Idrees
authors.forename: Mohammad Khan
authors.initials: MK
authors.lastname: Sarfraz
authors.forename: Muhammad Khalid
authors.initials: MK
authors.lastname: Khan
authors.forename: Ghulam
authors.initials: G
authors.lastname: Mustafa
mesh_terms: D000420:Albuterol / Q000008:administration & dosage / Q000737:chemistry*; D002214:Capsules / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003692:Delayed-Action Preparations / Q000737:chemistry*; D005079:Excipients / Q000737:chemistry*; D005223:Fats / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D057927:Hydrophobic and Hydrophilic Interactions; D007700:Kinetics; D009821:Oils / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry; D012995:Solubility
chemical_list: D002214:Capsules; D003692:Delayed-Action Preparations; D005079:Excipients; D005223:Fats; D009821:Oils; D011108:Polymers; C071184:Gelucire 50-13; D000420:Albuterol